Product Description
a novel enhancer of somatostatin release; FK962 (N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide) is a derivative of FK960 (N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate), with putative anti-dementia properties. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16325809/)
Mechanisms of Action: Somatostatin Release Agonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00087724 |
NCT00087724 | P2 |
Terminated |
Alzheimer Disease |
None |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|